Moyle G
Chelsea and Westminster Hospital, London, United Kingdom.
Clin Ther. 2000 Aug;22(8):911-36; discussion 898. doi: 10.1016/S0149-2918(00)80064-8.
This article reviews the clinical manifestations of mitochondrial toxicity associated with the use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and outlines strategies to manage these sequelae.
NRTIs are the key components of the antiretroviral combinations used in the management of patients infected with HIV. The available NRTIs differ in their convenience of administration, frequency of dosing, resistance profiles, and side-effect profiles. NRTIs act as competitive inhibitors of the RNA/DNA polymerase reverse transcriptase of HIV and cause chain termination in the growing viral DNA chain. Many of the important and treatment-limiting side effects of NRTIs may be related to the effect of these agents on human DNA polymerases, in particular, mitochondrial DNA polymerase gamma. Depletion of mitochondrial DNA during chronic NRTI therapy may lead to cellular respiratory dysfunction and generalized and tissue- and drug-specific toxicities, including myopathy, peripheral neuropathy, and lactic acidosis. Recently, it has been proposed that the fat redistribution syndrome, or lipodystrophy, reported during chronic antiretroviral therapy is a manifestation of the differential impact of at least some NRTIs on peripheral and visceral adipocytes. Management of potential mitochondrial toxicity during NRTI therapy remains a challenge. A range of nutritional supplements, both as treatments and prophylaxes, have been proposed, and some have been investigated in vitro; no in vivo studies have yet been conducted.
The information in this review was compiled using MEDLINE and AIDSLINE searches of the literature, including conference abstracts.
At present, interruption of NRTI therapy or substitution of the probable causative agent with alternative NRTIs that appear to be better tolerated represents the mainstay of management for mitochondrial toxicity and its clinical manifestations.
本文回顾了与核苷类逆转录酶抑制剂(NRTIs)使用相关的线粒体毒性的临床表现,并概述了处理这些后遗症的策略。
NRTIs是用于治疗HIV感染患者的抗逆转录病毒联合用药的关键组成部分。现有的NRTIs在给药便利性、给药频率、耐药谱和副作用谱方面存在差异。NRTIs作为HIV的RNA/DNA聚合酶逆转录酶的竞争性抑制剂,可导致正在生长的病毒DNA链发生链终止。NRTIs许多重要的、限制治疗的副作用可能与这些药物对人类DNA聚合酶,特别是线粒体DNA聚合酶γ的作用有关。慢性NRTI治疗期间线粒体DNA的耗竭可能导致细胞呼吸功能障碍以及全身性、组织特异性和药物特异性毒性,包括肌病、周围神经病变和乳酸性酸中毒。最近有人提出,慢性抗逆转录病毒治疗期间报告的脂肪重新分布综合征或脂肪代谢障碍是至少一些NRTIs对周围和内脏脂肪细胞产生不同影响的表现。NRTI治疗期间潜在线粒体毒性的管理仍然是一项挑战。已经提出了一系列营养补充剂用于治疗和预防,其中一些已在体外进行研究;尚未进行体内研究。
本综述中的信息是通过对MEDLINE和AIDSLINE文献检索(包括会议摘要)汇编而成的。
目前,中断NRTI治疗或用耐受性似乎更好的替代NRTIs替换可能的致病药物是线粒体毒性及其临床表现管理的主要方法。